Cargando…
Novel anti-apoptotic L-DOPA precursors SuperDopa and SuperDopamide as potential neuroprotective agents for halting/delaying progression of Parkinson’s disease
Parkinson’s disease (PD) is characterized by a gradual degeneration of the dopaminergic neurons in the substantia nigra pars compacta (SNpC). Levodopa, the standard PD treatment, provides the missing dopamine in SNpC, but ultimately after a honeymoon with levodopa treatment the neurodegenerative pro...
Autores principales: | Wiesen, Tom, Atlas, Daphne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917195/ https://www.ncbi.nlm.nih.gov/pubmed/35277478 http://dx.doi.org/10.1038/s41419-022-04667-2 |
Ejemplares similares
-
Curcumin modulation of L-dopa and rasagiline-induced neuroprotection in rotenone model of Parkinson’s disease
por: El-Shamarka, Marwa El-Sayed, et al.
Publicado: (2023) -
L-DOPA
por: Hornykiewicz, Oleh
Publicado: (2017) -
L-DOPA-therapy in Parkinson’s disease: some personal reflections on L-DOPA therapy from Vienna and Berlin
por: Riederer, Peter, et al.
Publicado: (2023) -
L-Dopa and Behavior
por: Kebabian, John
Publicado: (1974) -
Dopa Responsive Slow Orthostatic Tremor in Parkinson’s Disease
por: Lee, Suk Yoon, et al.
Publicado: (2011)